Prescription drug sales at 340B prices grew 12.2% year-on-year from 2021 to 2022, drug industry consulting and research firm IQVIA says in a new white paper. That is down 3.7 percentage points compared with 340B sales growth from 2020 to 2021 and down 5.9 percentage points from 2019 to 2020.
IQVIA reported last year that 340B sales grew 15.9% year-on-year from 2020 to 2021. Before that it reported 340B sales growth of 18.1% from 2019 to 2020 and 17.1% from 2018 to 2019. Drug manufacturers began restricting sales at 340B prices in mid 2020, a trend that accelerated through 2022 and kept growing this year.
Prescription drug sales at 340B prices grew 12.2% year-on-year from 2021 to 2022, drug industry consulting and research firm IQVIA says in a new white paper. That is down 3.7 percentage points compared with 340B sales growth from 2020 to […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.